Published on: April 16, 2025 |
By: WealthMintr Team
Here are some reasons it may have gapped Down: 1) Negative Clinical Trial Results: Initial data from the Phase 2 clinical trial for VCIG’s lead drug candidate, targeting a rare autoimmune disease, showed limited efficacy and a higher-than-expected incidence of adverse side effects, as announced this morning. 2) Concerns about Cash Runway: The company’s....
Continue Reading